Cas no 1219802-61-5 (Hexadecanoic-2,2,16,16,16-d5 Acid)
Hexadecanoic-2,2,16,16,16-d5 Acid Chemical and Physical Properties
Names and Identifiers
-
- Hexadecanoic-2,2,16,16,16-d5 Acid
-
- Inchi: 1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)
- InChI Key: IPCSVZSSVZVIGE-UHFFFAOYSA-N
- SMILES: C(CCCC([H])([H])C(=O)O)CCCCCCCCCC([H])([H])[H]
Hexadecanoic-2,2,16,16,16-d5 Acid Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | P144529-2.5mg |
Hexadecanoic-2,2,16,16,16-d5 Acid |
1219802-61-5 | 2.5mg |
$ 64.00 | 2023-09-06 | ||
| TRC | P144529-5mg |
Hexadecanoic-2,2,16,16,16-d5 Acid |
1219802-61-5 | 5mg |
$ 81.00 | 2023-09-06 | ||
| TRC | P144529-25mg |
Hexadecanoic-2,2,16,16,16-d5 Acid |
1219802-61-5 | 25mg |
$144.00 | 2023-05-17 |
Hexadecanoic-2,2,16,16,16-d5 Acid Related Literature
-
Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
-
Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
-
Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
-
Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
-
Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
Additional information on Hexadecanoic-2,2,16,16,16-d5 Acid
Research Brief on Hexadecanoic-2,2,16,16,16-d5 Acid (CAS: 1219802-61-5) in Chemical Biology and Pharmaceutical Applications
Hexadecanoic-2,2,16,16,16-d5 Acid, a deuterated analog of palmitic acid (CAS: 1219802-61-5), has emerged as a critical tool in metabolic research and drug development due to its stable isotopic labeling. Recent studies highlight its utility in tracing lipid metabolism, investigating metabolic disorders, and enhancing the precision of pharmacokinetic studies. This research brief synthesizes the latest findings on this compound, focusing on its applications, mechanisms, and emerging trends in chemical biology and pharmaceutical sciences.
A 2023 study published in Journal of Lipid Research demonstrated the compound's pivotal role in quantifying endogenous palmitate flux using mass spectrometry. The deuterium labeling at specific positions (2,2,16,16,16-d5) minimizes isotopic interference while maintaining metabolic integrity, enabling researchers to distinguish exogenous from endogenous fatty acid pools with unprecedented accuracy. This approach has been particularly valuable in studying obesity-related metabolic dysregulation.
In pharmaceutical formulation, Hexadecanoic-2,2,16,16,16-d5 Acid serves as an internal standard for LC-MS/MS analysis of lipid-based drug delivery systems. A recent patent (WO2023056321) describes its incorporation into nanoparticle formulations to track biodistribution profiles of anticancer agents. The deuterium labeling pattern provides distinct mass spectral signatures without altering the compound's physicochemical properties, making it ideal for in vivo tracking studies.
Emerging applications include its use in NMR-based structural studies of membrane proteins. The selective deuteration allows for resolution enhancement in 1H-13C correlation spectra, as reported in ACS Chemical Biology (2024). Researchers have leveraged this property to investigate protein-lipid interactions in G-protein coupled receptors (GPCRs), providing insights into drug binding mechanisms.
The synthesis and purification of Hexadecanoic-2,2,16,16,16-d5 Acid have seen significant advancements. A 2024 Organic Process Research & Development paper details an improved catalytic deuteration method using Pd/C in D2O, achieving >98% isotopic purity at reduced production costs. This development addresses previous challenges in large-scale production, potentially expanding its use in clinical tracer studies.
Ongoing clinical trials (NCT05678984) are evaluating this deuterated fatty acid as a diagnostic tracer for non-alcoholic steatohepatitis (NASH). Preliminary data suggest its potential to quantify hepatic lipid turnover rates more accurately than conventional imaging techniques. Regulatory considerations for such applications are being actively discussed, particularly regarding Good Manufacturing Practice (GMP) standards for deuterated biomarkers.
Future research directions include exploring its utility in single-cell metabolomics and as a probe for studying lipid peroxidation in neurodegenerative diseases. The compound's unique labeling pattern offers distinct advantages for multiplexed metabolic flux analysis when combined with other isotopically labeled nutrients, opening new avenues for systems biology approaches.
1219802-61-5 (Hexadecanoic-2,2,16,16,16-d5 Acid) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)